{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:59:08Z","timestamp":1785466748923,"version":"3.56.0"},"reference-count":44,"publisher":"American Chemical Society (ACS)","issue":"6","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100019542","name":"Basic Research Project of Wenzhou City","doi-asserted-by":"publisher","award":["Y2023932"],"award-info":[{"award-number":["Y2023932"]}],"id":[{"id":"10.13039\/501100019542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["nos. 82204217"],"award-info":[{"award-number":["nos. 82204217"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Type 2 diabetes mellitus requires therapies that optimize both efficacy and durability. Although incretin mimetics such as exendin-4 (Ex4) enhance glycemic control, their short half-life restricts their clinical utility. Current extension strategies (e.g., Fc fusion) encounter challenges including immunogenicity and manufacturing complexity. Here, we engineered a series of site-specific IgG Fc-binding motif-modified Ex4 analogues using two orthogonal conjugation methods, leveraging Fc-III-4C-mediated IgG binding (human IgG: KD = 20.1 nM) to achieve a significantly extended plasma half-life. Structure\u2013activity relationship studies revealed that the lead candidate, conjugate 7, retained robust GLP-1R activation and acute glucose-lowering efficacy. In human IgG-preconditioned db\/db mice, conjugate 7 achieved a hypoglycemic duration comparable to that of semaglutide. Chronic once-daily dosing of the lead conjugate rivaled semaglutide in reducing HbA1c and protecting pancreatic islets, without toxicity. This strategy leverages &amp;gt;80% of endogenous circulating IgG as a biological reservoir to overcome peptide therapy limitations, offering a translatable platform for long-acting antidiabetic agents.<\/jats:p>","DOI":"10.1021\/acs.bioconjchem.6c00218","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T13:23:12Z","timestamp":1780147392000},"page":"1292-1302","source":"Crossref","is-referenced-by-count":0,"title":["IgG Fc-Binding\nMotif-Conjugated Exendin-4: A Long-Acting\nHypoglycemic Agent via Broad-Spectrum Antibody Engagement for Type\n2 Diabetes Therapy"],"prefix":"10.1021","volume":"37","author":[{"given":"Baojing","family":"Mi","sequence":"first","affiliation":[{"name":"Wenzhou Medical University , , , ,","place":["Wenzhou, Zhejiang, China, 325035"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjie","family":"Ding","sequence":"additional","affiliation":[{"name":"Xinchang Hospital of Wenzhou Medical University , , , ,","place":["Shaoxing, Zhejiang, China, 312500"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Tian","sequence":"additional","affiliation":[{"name":"Wenzhou Medical University , , , ,","place":["Wenzhou, Zhejiang, China, 325035"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhong","family":"Yu","sequence":"additional","affiliation":[{"name":"Wenzhou Medical University , , , ,","place":["Wenzhou, Zhejiang, China, 325035"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengxuan","family":"Ji","sequence":"additional","affiliation":[{"name":"Wenzhou Medical University , , , ,","place":["Wenzhou, Zhejiang, China, 325035"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luwei","family":"Fu","sequence":"additional","affiliation":[{"name":"Wenzhou Medical University , , , ,","place":["Wenzhou, Zhejiang, China, 325035"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Liu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Wenzhou Medical University , , ,","place":["Wenzhou, China, 325000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuepiao","family":"Cai","sequence":"additional","affiliation":[{"name":"Wenzhou Medical University , , , ,","place":["Wenzhou, Zhejiang, China, 325035"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2710-0966","authenticated-orcid":true,"given":"Shijie","family":"Dai","sequence":"additional","affiliation":[{"name":"Wenzhou Medical University , , , ,","place":["Wenzhou, Zhejiang, China, 325035"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"2026073022121010100_cit1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.19","article-title":"Type 2 diabetes mellitus","volume":"1","author":"DeFronzo","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"7","key":"2026073022121010100_cit2","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41574-025-01114-y","article-title":"Insulin resistance\nin type 2 diabetes\nmellitus","volume":"21","author":"Accili","year":"2025","journal-title":"Nat. Rev. Endocrinol."},{"issue":"7","key":"2026073022121010100_cit3","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41574-022-00669-4","article-title":"Pathophysiology,\nphenotypes and management of type 2 diabetes mellitus in Indian and\nChinese populations","volume":"18","author":"Ke","year":"2022","journal-title":"Nat. Rev. Endocrinol."},{"issue":"3","key":"2026073022121010100_cit4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ecl.2021.05.013","article-title":"An Update on the Epidemiology of Type 2 Diabetes: A\nGlobal Perspective","volume":"50","author":"Tinajero","year":"2021","journal-title":"Endocrinol. Metab. Clin.\nNorth Am."},{"key":"2026073022121010100_cit5","unstructured":"International Diabetes Federation.\n          .  IDF Diabetes Atlas, 11th edn, https:\/\/diabetesatlas.org\/atlas\/eleventh-edition\/(2025)."},{"issue":"14","key":"2026073022121010100_cit6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1118848","article-title":"Pharmacological approaches\nto the prevention of type 2 diabetes mellitus","volume":"14","author":"Majety","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"6","key":"2026073022121010100_cit7","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1021\/acs.molpharmaceut.9b00308","article-title":"Glucagon-Like Peptide-1\nReceptor\nAgonists and Strategies To Improve Their Efficiency","volume":"16","author":"Alavi","year":"2019","journal-title":"Mol. Pharmaceutics"},{"key":"2026073022121010100_cit8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.addr.2018.07.009","article-title":"Battle of GLP-1 delivery technologies","volume":"130","author":"Yu","year":"2018","journal-title":"Adv. Drug Delivery Rev."},{"issue":"3","key":"2026073022121010100_cit9","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1021\/jm500810s","article-title":"Glucagon-like peptide-1 (GLP-1) analogs:\nrecent advances,\nnew possibilities, and therapeutic implications","volume":"58","author":"Manandhar","year":"2015","journal-title":"J. Med. Chem."},{"key":"2026073022121010100_cit10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116342","article-title":"Glucagon-like\npeptide-1 analogs: Miracle drugs are blooming?","volume":"269","author":"Gong","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"2026073022121010100_cit11","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1080\/19420862.2015.1019788","article-title":"Fusion protein technologies\nfor biopharmaceuticals:\nApplications and challenges: Editor Stefan R Schmidt","volume":"7","author":"Berger","year":"2015","journal-title":"MAbs"},{"issue":"1","key":"2026073022121010100_cit12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0168-3659(02)00462-5","article-title":"Accelerated\nclearance of PEGylated liposomes in rats after repeated injections","volume":"88","author":"Ishida","year":"2003","journal-title":"J. Controlled Release"},{"issue":"1","key":"2026073022121010100_cit13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic\npeptides: current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduction Targeted Ther."},{"issue":"8","key":"2026073022121010100_cit14","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1021\/acs.jmedchem.1c00032","article-title":"Exendin 4-Hapten\nConjugate Capable of Binding with Endogenous Antibodies for Peptide\nHalf-life Extension and Exerting Long-Acting Hypoglycemic Activity","volume":"64","author":"Dai","year":"2021","journal-title":"J. Med. Chem."},{"issue":"378","key":"2026073022121010100_cit15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jconrel.2024.11.080","article-title":"Reconstituting the immune killing\nfunctions and improving the pharmacokinetics of nanobodies by rhamnolipid\nconjugation","volume":"378","author":"Li","year":"2025","journal-title":"J. Controlled Release"},{"issue":"12","key":"2026073022121010100_cit16","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.1039\/D0SC00017E","article-title":"Fc-binding\nantibody-recruiting molecules\nexploit endogenous antibodies for anti-tumor immune responses","volume":"11","author":"Sasaki","year":"2020","journal-title":"Chem. Sci."},{"issue":"12","key":"2026073022121010100_cit17","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.1039\/D0SC05332E","article-title":"Universal endogenous\nantibody recruiting nanobodies capable of triggering immune effectors\nfor targeted cancer immunotherapy","volume":"12","author":"Hong","year":"2021","journal-title":"Chem. Sci."},{"issue":"1","key":"2026073022121010100_cit18","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s12325-021-01921-5","article-title":"Pharmacokinetics, Pharmacodynamics,\nand Safety of Dulaglutide After\nSingle or Multiple Doses in Chinese Healthy Subjects and Patients\nwith T2DM: A Randomized, Placebo-Controlled, Phase I Study","volume":"39","author":"Xu","year":"2022","journal-title":"Adv. Ther."},{"issue":"8","key":"2026073022121010100_cit19","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1002\/bit.27374","article-title":"Engineered human\nFc\u03b3RIIa fusion:\nA novel strategy to extend serum half-life of therapeutic proteins","volume":"117","author":"Jo","year":"2020","journal-title":"Biotechnol. Bioeng."},{"issue":"12","key":"2026073022121010100_cit20","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3390\/ma9120994","article-title":"Fc-Binding Ligands of Immunoglobulin\nG: An Overview of High Affinity Proteins and Peptides","volume":"9","author":"Choe","year":"2016","journal-title":"Materials"},{"issue":"8","key":"2026073022121010100_cit21","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1021\/ja057513w","article-title":"Protein ligand design:\nfrom phage display to synthetic\nprotein epitope mimetics in human antibody Fc-binding peptidomimetics","volume":"128","author":"Dias","year":"2006","journal-title":"J. Am. Chem. Soc."},{"issue":"5456","key":"2026073022121010100_cit22","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1126\/science.287.5456.1279","article-title":"Convergent solutions\nto binding at a protein-protein interface","volume":"287","author":"DeLano","year":"2000","journal-title":"Science"},{"issue":"7","key":"2026073022121010100_cit23","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1021\/acs.bioconjchem.6b00170","article-title":"Development\nof the Double Cyclic Peptide Ligand for Antibody Purification and\nProtein Detection","volume":"27","author":"Gong","year":"2016","journal-title":"Bioconjugate Chem."},{"issue":"7","key":"2026073022121010100_cit24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0102566","article-title":"Fusion of a Short\nPeptide that Binds Immunoglobulin G to a Recombinant Protein Substantially\nIncreases Its Plasma Half-Life in Mice","volume":"9","author":"Hagemeyer","year":"2014","journal-title":"PLoS\nOne"},{"issue":"12","key":"2026073022121010100_cit25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008082","article-title":"IgG Fc-binding\nmotif-conjugated HIV-1 fusion inhibitor exhibits improved potency\nand in vivo half-life: Potential application in combination with broad\nneutralizing antibodies","volume":"15","author":"Bi","year":"2019","journal-title":"PLoS Pathog."},{"issue":"8","key":"2026073022121010100_cit26","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1021\/acs.bioconjchem.8b00395","article-title":"Development\nand Characterization of Peptide Ligands of Immunoglobulin G Fc Region","volume":"29","author":"Kruljec","year":"2018","journal-title":"Bioconjugate Chem."},{"issue":"7","key":"2026073022121010100_cit27","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1021\/acs.bioconjchem.6b00149","article-title":"Novel Hybrid Compound of a Plinabulin Prodrug\nwith an IgG Binding Peptide for Generating a Tumor Selective Noncovalent-Type\nAntibody-Drug Conjugate","volume":"27","author":"Muguruma","year":"2016","journal-title":"Bioconjugate Chem."},{"issue":"9","key":"2026073022121010100_cit28","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1007\/s13233-015-3118-x","article-title":"IgG Fc-binding peptide\n(FcBP)-tat conjugate as a smart antibody carrier into live cells","volume":"23","author":"Kang","year":"2015","journal-title":"Macromol. Res."},{"issue":"1","key":"2026073022121010100_cit29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ab.2007.10.022","article-title":"Controlled\nantibody immobilization\nonto immunoanalytical platforms by synthetic peptide","volume":"374","author":"Jung","year":"2008","journal-title":"Anal. Biochem."},{"issue":"2","key":"2026073022121010100_cit30","first-page":"473","article-title":"Serum IgG subclass\nconcentrations in healthy adults:\na study using monoclonal antisera","volume":"56","author":"French","year":"1984","journal-title":"Clin. Exp.\nImmunol."},{"issue":"10","key":"2026073022121010100_cit31","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1093\/clinchem\/41.10.1475","article-title":"Subclass typing of\nIgG paraproteins by immunofixation electrophoresis","volume":"41","author":"Klouche","year":"1995","journal-title":"Clin. Chem."},{"issue":"1","key":"2026073022121010100_cit32","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1080\/07328303.2011.635251","article-title":"Sortase-Mediated Transpeptidation\nfor Site-Specific Modification\nof Peptides, Glycopeptides, and Proteins","volume":"31","author":"Wu","year":"2012","journal-title":"J.\nCarbohydr. Chem."},{"issue":"7","key":"2026073022121010100_cit33","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1021\/acs.bioconjchem.0c00291","article-title":"Optimized\nMethods\nfor the Production and Bioconjugation of Site-Specific, Alkyne-Modified\nGlucagon-like Peptide-1 (GLP-1) Analogs to Azide-Modified Delivery\nPlatforms Using Copper-Catalyzed Alkyne\u2013Azide Cycloaddition","volume":"31","author":"Alavi","year":"2020","journal-title":"Bioconjugate Chem."},{"key":"2026073022121010100_cit34","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2020.116864","article-title":"Site-selective modification\nof exendin 4 with variable molecular weight dextrans by oxime-ligation\nchemistry for improving type 2 diabetic treatment","volume":"249","author":"Dai","year":"2020","journal-title":"Carbohydr. Polym."},{"issue":"5","key":"2026073022121010100_cit35","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.jmb.2019.08.009","article-title":"New Insights into Beta-Cell\nGLP-1\nReceptor and cAMP Signaling","volume":"432","author":"Tomas","year":"2020","journal-title":"J. Mol. Biol."},{"issue":"21","key":"2026073022121010100_cit36","doi-asserted-by":"publisher","first-page":"5952","DOI":"10.1016\/j.bmc.2017.09.010","article-title":"3rd. In vivo programming\nof endogenous antibodies via oral administration of adaptor ligands","volume":"25","author":"Nagano","year":"2017","journal-title":"Bioorg. Med. Chem."},{"issue":"17","key":"2026073022121010100_cit37","doi-asserted-by":"publisher","first-page":"15373","DOI":"10.1021\/acs.jmedchem.4c00967","article-title":"Chemoenzymatic\nSynthesis of DNP-Functionalized FGFR1-Binding Peptides as Novel Peptidomimetic\nImmunotherapeutics for Treating Lung Cancer","volume":"67","author":"Li","year":"2024","journal-title":"J. Med. Chem."},{"issue":"7","key":"2026073022121010100_cit38","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1021\/cb300119g","article-title":"Antibody-recruiting\nmolecules: an emerging paradigm for engaging immune function in treating\nhuman disease","volume":"7","author":"McEnaney","year":"2012","journal-title":"ACS Chem. Biol."},{"issue":"12","key":"2026073022121010100_cit39","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/intimm\/13.12.1551","article-title":"Differences in promiscuity\nfor antibody-FcRn interactions across species: implications for therapeutic\nantibodies","volume":"13","author":"Ober","year":"2001","journal-title":"Int. Immunol."},{"issue":"7","key":"2026073022121010100_cit40","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1074\/jbc.M109.081828","article-title":"Cross-species binding analyses of mouse and human neonatal\nFc receptor show dramatic differences in immunoglobulin G and albumin\nbinding","volume":"285","author":"Terje Andersen","year":"2010","journal-title":"J. Biol. Chem."},{"key":"2026073022121010100_cit41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115470","article-title":"A precisely\nhumanized\nFCRN transgenic mouse for preclinical pharmacokinetics studies","volume":"210","author":"Conner","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"24","key":"2026073022121010100_cit42","doi-asserted-by":"publisher","first-page":"20819","DOI":"10.1021\/jacs.5c04095","article-title":"Molecular Design of Unimolecular Tetra-Receptor Agonists","volume":"147","author":"Dinsmore","year":"2025","journal-title":"J. Am. Chem. Soc."},{"issue":"6","key":"2026073022121010100_cit43","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide\nversus Semaglutide Once Weekly in Patients\nwith Type 2 Diabetes","volume":"385","author":"Fri\u0301as","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"2026073022121010100_cit44","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2022.103464","article-title":"Peptide-based drug\ndiscovery: Current status and recent advances","volume":"28","author":"Sharma","year":"2023","journal-title":"Drug Discovery Today"}],"container-title":["Bioconjugate Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.bioconjchem.6c00218","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/6\/1292\/66265327\/acs.bioconjchem.6c00218.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/6\/1292\/66265327\/acs.bioconjchem.6c00218.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:12:15Z","timestamp":1785463935000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/bcches\/article\/37\/6\/1292\/5233107\/IgG-Fc-Binding-Motif-Conjugated-Exendin-4-A-Long"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,5,30]]},"published-print":{"date-parts":[[2026,6,17]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.bioconjchem.6c00218","relation":{},"ISSN":["1043-1802","1520-4812"],"issn-type":[{"value":"1043-1802","type":"print"},{"value":"1520-4812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]}}}